SCHEMBL2086167

SCHEMBL2086167

CC1CCN(c2c(-c3ccccc3Cl)cnc3c(C(=O)NC(C)(C)c4ccccn4)cnn23)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
GRM4 Q14833 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
LMNA P02545 2/20 0.35
TSHR P16473 1/20 0.35
HSD11B1 P28845 1/20 0.35
NPC1 O15118 2/20 0.35
NPY2R P49146 1/20 0.34
IMPDH2 P12268 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 2/20 0.34
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
IRAK4 Q9NWZ3 2/20 0.33
SYK P43405 1/20 0.33
TRPV1 Q8NER1 1/20 0.33
ADORA2A P29274 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2084476 0.91 CNR1 (0.36) KMT2AMEN1CNR1CNR2NPY2R
SCHEMBL2085537 0.89 TYK2 (0.37) KMT2AMEN1CNR1CNR2IMPDH2
SCHEMBL2085113 0.83 KMT2A (0.45) ALDH1A1KMT2AMEN1CNR2LMNA
SCHEMBL2085817 0.79 MAPT (0.39) ALDH1A1KMT2ALMNANPC1IMPDH2
SCHEMBL2086791 0.77 KDM4E (0.46) ALDH1A1KMT2ALMNANPC1RAB9A
SCHEMBL2085340 0.77 GPR119 (0.39) GRM4LMNAIMPDH2TRPV1
SCHEMBL8983202 0.72 CNR1 (0.43) ALDH1A1KMT2AMEN1CNR1CNR2
SCHEMBL4120324 0.71 GPR119 (0.39) ALDH1A1KMT2AMEN1CNR1CNR2
SCHEMBL4121602 0.70 KDM4E (0.46) ALDH1A1LMNANPC1RAB9AMAPT
SCHEMBL4120972 0.69 KDM4E (0.44) ALDH1A1LMNANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921380-B2 Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-12-30 US claimed
EP-2035427-B1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORP (JP) 2013-12-11 EP claimed
US-20120202992-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST TANIMOTO KOICHI (JP) 2012-08-09 US claimed
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-15 US claimed
US-8921380-B2 Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-12-30 US disclosed
EP-2520577-A1 Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonists Mitsubishi Tanabe Pharma Corporation (JP) 2012-11-07 EP disclosed
US-20120202992-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST TANIMOTO KOICHI (JP) 2012-08-09 US disclosed
US-8163759-B2 Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-04-24 US disclosed
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202992-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST CNR1, CNR2, CCKAR ALDH1A1 2507/4885GRM4 403/4885KMT2A 2533/4885
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST CNR1, CNR2, CCKAR ALDH1A1 2256/4885GRM4 391/4885KMT2A 2273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.